FDA Warns Mylan Over Quality Concerns At India Facility
Category: HEALTHY LIVING
Violations included a failure to “thoroughly investigate” unexplained discrepancies in drug batches and “missing, deleted, and lost data."
By Natalie Grover, Reuters, 2017-04-12